All compounds discussed here are supplied strictly for in vitro and laboratory research use only; they are not drugs, dietary supplements, or products intended for human or veterinary administration.
“Peptide bioregulator” is a category label rather than a single mechanism. It refers to a family of very short synthetic peptides — usually two to four amino acids — developed principally by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, and studied in preclinical models under the hypothesis that short peptides can act as sequence-specific regulators of gene expression. Researchers encountering the category for the first time tend to notice two things immediately: the molecules are far smaller than the peptides that dominate the rest of the research market, and each one is assigned in the literature to a particular tissue system.
Where the category came from
The lineage begins with peptide-containing extracts of animal tissue rather than with designed molecules. Work in Leningrad through the 1970s and 1980s characterized fractions of bovine thymus (described in that literature as Thymalin) and pineal gland (Epithalamin), and reported that measurable activity in cell and animal models tracked with the lowest-molecular-weight fractions. Subsequent fractionation and sequencing work led to the synthesis of defined short peptides intended to reproduce those fractions’ behavior in the same assays.
Two synthetic peptides became the reference points for everything that followed: Vilon (Lys-Glu, often written KE), derived from the thymic work, and Epitalon (Ala-Glu-Asp-Gly, AEDG), derived from the pineal work. The remainder of the catalog extends the same design logic outward — a short acidic or basic sequence associated in the source literature with a specific organ system.
What structurally defines a bioregulator
- Length. Two to four residues, with molecular weights roughly in the 250–450 Da range — an order of magnitude smaller than peptides such as BPC-157 or TB-500.
- Composition. Unmodified L-amino acids, overwhelmingly glutamate, aspartate, and lysine. No cyclization, no unnatural residues, no lipidation.
- No proposed receptor. Unlike GLP or growth-hormone-secretagogue research peptides, the bioregulator literature does not assign these molecules a cell-surface receptor. The proposed site of action is intracellular and, specifically, nuclear.
- Tissue assignment. Each compound carries a designation tying it to a tissue system in the originating research, which is why the category is frequently described as “tissue-specific” — a description that reflects the research framing, not a demonstrated targeting mechanism.
The practical consequence of that size is a very short expected plasma residence time, which is part of why the literature’s mechanistic model is transcriptional rather than pharmacodynamic: the hypothesis is that low concentrations produce durable changes in gene expression, not that sustained exposure produces a sustained signal.
The proposed mechanism
Nuclear localization
Studies using fluorescently labeled short peptides have reported their appearance in the nuclei and nucleoli of cultured cells, indicating that molecules of this size are not excluded from the nuclear compartment. The same work described binding interactions between labeled short peptides and synthetic deoxyribooligonucleotides in vitro.
Sequence-complementary DNA interaction
The central mechanistic claim is that a given short peptide interacts preferentially with particular double-stranded DNA sequences — typically framed as promoter-region binding, with molecular-modeling work proposing accommodation in the major groove and a sensitivity to CG content and cytosine methylation state. On this model, a dipeptide or tetrapeptide functions less like a signaling ligand and more like a small, highly selective transcriptional modulator.
Reported downstream observations
Downstream endpoints reported in this literature include altered chromatin condensation state in cultured lymphocytes, changes in the expression of individual genes in tissue-specific assays, and, for AEDG, telomerase activity and telomere elongation in cultured human somatic cells. These are cell- and animal-model observations; they have not been established as human outcomes, and the concentration ranges, assay systems, and reported effect sizes vary considerably across reports.
Compounds in the category
| Bioregulator | Sequence | Residues | Tissue system in the source literature |
|---|---|---|---|
| Vilon | Lys-Glu (KE) | 2 | Thymic / immune-cell models |
| Vesugen | Lys-Glu-Asp (KED) | 3 | Vascular endothelial models |
| Livagen | Lys-Glu-Asp-Ala (KEDA) | 4 | Hepatic tissue and lymphocyte chromatin studies |
| Cartalax | Ala-Glu-Asp-Pro (AEDP) | 4 | Cartilage and connective-tissue models |
| Epitalon | Ala-Glu-Asp-Gly (AEDG) | 4 | Pineal / senescence models |
| Pinealon | Glu-Asp-Arg (EDR) | 3 | Neuronal culture models |
| Bronchogen | Ala-Glu-Asp-Leu (AEDL) | 4 | Respiratory epithelium models |
| Cardiogen | Ala-Glu-Asp-Arg (AEDR) | 4 | Myocardial tissue models |
| Thymogen | Glu-Trp (EW) | 2 | Thymic / immune-cell models |
What the evidence base does and does not support
Researchers evaluating this category should weigh several structural features of its literature. The large majority of primary reports originate from a single research school and were published in Russian-language journals such as Bulletin of Experimental Biology and Medicine and Advances in Gerontology, often with small sample sizes and limited methodological detail by contemporary standards. Independent blinded replication of the core DNA-binding and gene-expression findings remains sparse, and no consensus transport mechanism or binding-site model has been established outside that body of work. None of these compounds is an approved drug in the United States or European Union.
That is not an argument that the mechanistic hypothesis is wrong — it is an argument that it remains an open question, and that experiments in this space are best designed with independent controls rather than on the assumption that the reported effects are settled.
Analytical identity matters unusually much here
Because the sequences are so short and so closely related, several bioregulators differ from one another by a single residue: KE, KED, and KEDA are a dipeptide, tripeptide, and tetrapeptide built on the same N-terminal motif. Appearance, solubility, and lyophilized mass provide no way to tell them apart, so mass-spectrometric identity and HPLC purity data are the only practical verification. Current analytical documentation for the catalog is published in the COA library.
Handling in the laboratory follows the same conventions as other lyophilized research peptides: store as received per the accompanying certificate, and calculate working concentrations as straightforward laboratory arithmetic — mass of peptide divided by volume of diluent — using the reconstitution calculator. These figures describe solution concentration for in vitro work only and are not administration guidance of any kind.
References
- Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). 2011;76(11):1210–1219. PMID: 22117547.
- Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139–149. PMID: 19830585.
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590–592. PMID: 12937682.
- Khavinson VKh. Neuroendocrinology Letters. 2002; supplement volume — monograph-length review of the short-peptide bioregulator programme.
- Kozina LS, Arutjunyan AV, Khavinson VKh. Archives of Gerontology and Geriatrics. 2007; supplement 1 — in vitro antioxidant characterization of pineal-derived short peptides.
- Khavinson VKh, Solovyov AYu, Zhilinskiy DV, et al. Bulletin of Experimental Biology and Medicine. Molecular-modeling reports on short-peptide interaction with promoter-region DNA.
- Preclinical studies have additionally examined tissue-specific short peptides in rodent models of tissue senescence; these reports are distributed across Russian-language gerontology journals and are not consistently indexed with English-language abstracts.
Reviewed for research accuracy: July 30, 2026
Research use only. The compounds described above are intended exclusively for laboratory research by qualified investigators. They are not approved for human or animal administration, diagnosis, treatment, or any other clinical application, and nothing on this page should be read as guidance for such use.